Clinicopathological features and treatment strategy for triple-negative breast cancer

摘要: Breast cancers are divided into at least 4 subtypes on the basis of gene expression profiles and receptors (hormone (HR) HER2) as measured by immunohistochemistry. These have different prognoses responses to treatments such endocrine manipulation, anti-HER2 therapy, chemotherapy. Triple-negative breast cancer (TNBC) is immunohistochemically defined lacking estrogen progesterone not overexpressing HER2. TNBC accounts for approximately 15% patients, more chemosensitive but has a worse prognosis than HR-positive/HER2-negative phenotype. heterogeneous disease that does offer specific targets in same way HR-positive HER2-positive cancers, similar basal-like BRCA1-related cancer. At present, lack highly effective therapeutic leaves standard chemotherapy, example combination anthracycline taxane, only medical treatment, this insufficiently efficacious. Novel approaches TNBC, DNA damaging agents, PARP-1 inhibitors, receptor tyrosin kinase inhibitors (TKIs), antiangiogenesis been examined clinical settings. Concerning strategies it most important develop novel treatment high-throughput predictive tools chemotherapy agents.